MX2010005115A - Anticuerpos anti-factor b y sus usos. - Google Patents

Anticuerpos anti-factor b y sus usos.

Info

Publication number
MX2010005115A
MX2010005115A MX2010005115A MX2010005115A MX2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A MX 2010005115 A MX2010005115 A MX 2010005115A
Authority
MX
Mexico
Prior art keywords
factor
antibodies
cnv
amd
antagonists
Prior art date
Application number
MX2010005115A
Other languages
English (en)
Spanish (es)
Inventor
Laura Deforge
Menno Van Lookeren Campagne
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40344464&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010005115(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2010005115A publication Critical patent/MX2010005115A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2010005115A 2007-11-08 2008-11-06 Anticuerpos anti-factor b y sus usos. MX2010005115A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US264807P 2007-11-08 2007-11-08
PCT/US2008/082621 WO2009061910A1 (en) 2007-11-08 2008-11-06 Anti-factor b antibodies and their uses

Publications (1)

Publication Number Publication Date
MX2010005115A true MX2010005115A (es) 2010-05-27

Family

ID=40344464

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005115A MX2010005115A (es) 2007-11-08 2008-11-06 Anticuerpos anti-factor b y sus usos.

Country Status (15)

Country Link
US (4) US8158762B2 (cg-RX-API-DMAC7.html)
EP (1) EP2209807A1 (cg-RX-API-DMAC7.html)
JP (1) JP2011503094A (cg-RX-API-DMAC7.html)
KR (1) KR20100105587A (cg-RX-API-DMAC7.html)
CN (1) CN101918444A (cg-RX-API-DMAC7.html)
AR (1) AR069233A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008323939A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0820343A2 (cg-RX-API-DMAC7.html)
CA (1) CA2704973A1 (cg-RX-API-DMAC7.html)
CL (1) CL2008003313A1 (cg-RX-API-DMAC7.html)
IL (1) IL205577A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010005115A (cg-RX-API-DMAC7.html)
PE (1) PE20091022A1 (cg-RX-API-DMAC7.html)
TW (1) TW200927170A (cg-RX-API-DMAC7.html)
WO (1) WO2009061910A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011003098A1 (en) 2009-07-02 2011-01-06 Musc Foundation For Research Development Methods of stimulating liver regeneration
TWI407953B (zh) * 2011-03-24 2013-09-11 Univ Kaohsiung Medical 用於調節補體因子ｂ（ｃｆｂ）表現的醫藥組合物
US9803005B2 (en) 2012-05-24 2017-10-31 Alexion Pharmaceuticals, Inc. Humaneered anti-factor B antibody
CN114890943A (zh) 2013-11-15 2022-08-12 阿克比治疗有限公司 {[5-(3-氯苯基)-3-羟基吡啶-2-羰基]氨基}乙酸固体形式，组合物和用途
EA201892225A1 (ru) 2016-04-04 2019-09-30 БИОВЕРАТИВ ЮЭсЭй ИНК. АНТИТЕЛА К ФАКТОРУ Bb КОМПЛЕМЕНТА И ИХ ПРИМЕНЕНИЕ
US11524939B2 (en) 2019-11-13 2022-12-13 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
AU2021261257A1 (en) 2020-04-20 2022-12-22 Genzyme Corporation Humanized anti-complement factor Bb antibodies and uses thereof

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4873191A (en) 1981-06-12 1989-10-10 Ohio University Genetic transformation of zygotes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4736866A (en) 1984-06-22 1988-04-12 President And Fellows Of Harvard College Transgenic non-human mammals
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
JP3040121B2 (ja) 1988-01-12 2000-05-08 ジェネンテク，インコーポレイテッド 増殖因子レセプターの機能を阻害することにより腫瘍細胞を処置する方法
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
DE69329503T2 (de) 1992-11-13 2001-05-03 Idec Pharma Corp Therapeutische Verwendung von chimerischen und markierten Antikörpern, die gegen ein Differenzierung-Antigen gerichtet sind, dessen Expression auf menschliche B Lymphozyt beschränkt ist, für die Behandlung von B-Zell-Lymphoma
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US20070123466A1 (en) * 2003-05-13 2007-05-31 New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery Method of treating recurrent miscarriages
DK1713503T3 (da) * 2004-02-10 2013-11-04 Univ Colorado Regents Hæmning af faktor b, den alternative komplemenpathway og dertil relaterede fremgangsmåde
NZ567483A (en) 2005-11-04 2012-04-27 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
DK1991275T3 (en) 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
EP2134173A4 (en) 2007-03-01 2010-11-10 Wellstat Ophthalmics Corp TREATMENT OF DISEASES SIGNED BY IGNITION

Also Published As

Publication number Publication date
US20180037667A1 (en) 2018-02-08
CL2008003313A1 (es) 2010-02-05
JP2011503094A (ja) 2011-01-27
WO2009061910A1 (en) 2009-05-14
PE20091022A1 (es) 2009-07-16
AU2008323939A1 (en) 2009-05-14
TW200927170A (en) 2009-07-01
CA2704973A1 (en) 2009-05-14
US20120230997A1 (en) 2012-09-13
US20090123469A1 (en) 2009-05-14
IL205577A0 (en) 2010-11-30
US20160024224A1 (en) 2016-01-28
US8158762B2 (en) 2012-04-17
EP2209807A1 (en) 2010-07-28
KR20100105587A (ko) 2010-09-29
CN101918444A (zh) 2010-12-15
AR069233A1 (es) 2010-01-06
BRPI0820343A2 (pt) 2017-08-22

Similar Documents

Publication Publication Date Title
MX2009012422A (es) Prevencion y tratamiento de afecciones del ojo asociadas con su complemento.
SG156649A1 (en) Crig polypeptide for prevention and treatment of complement-associated disorders
MX2010005115A (es) Anticuerpos anti-factor b y sus usos.
MY161495A (en) Virus like particle compositions and methods of use
WO2009129246A3 (en) Compositions and methods for preparing and using same
EA201290498A1 (ru) Терапевтические полимерные наночастицы, включающие эпотилон, и способы их получения и применения
MX351152B (es) Compstatina y analogos de la misma para tratar trastornos oculares.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
CY1113291T1 (el) Συνθεσεις και μεθοδοι για sirna αναστολη της αγγειογενεσης
EP2294184A4 (en) TREATMENT OF EYE DISEASES AND EXCESSIVE NEOVASCULARIZATION WITH THE HELP OF COMBINED THERAPY
TW200736275A (en) Methods and compositions for treating allergic diseases
MX348481B (es) Productos quimicos, composiciones y metodos para tratamiento y prevencion de infecciones de virus orthopox y enfermedades asociadas.
PH12013500577B1 (en) Compositions and methods for treating ocular edema, neovascularization and related diseases
WO2011071574A3 (en) Monoclonal antibodies against glycoprotein of ebola sudan boniface virus
MX2010010303A (es) Nuevos compuestos de acido ribonucleico de pequeña interferencia para inhibir rtp801.
WO2007098122A3 (en) Methods for the treatment of macular degeneration and related eye conditions
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
PH12022551228A1 (en) Trem2 antibodies and uses thereof
WO2008044217A3 (en) 2-aminocarbonyl-pyridine derivatives
WO2007133800A3 (en) Toll-like receptor (tlr) stimulation for ocular angiogenesis and macular degeneration
WO2006039327A3 (en) Methods of treatment or prophylaxis of amyloidogenic diseases of the eye or optic nerve
IN2012DN03361A (cg-RX-API-DMAC7.html)
WO2008048675A3 (en) Treatment for age-related macular degeneration and other diseases of the eye
TW200833248A (en) Bisoximes as fungicides
HK1255695A1 (zh) 用於治疗眼睑下垂的组合物和方法